drugset / Trial / NCT07574528
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter phase II study evaluating sintilimab, pegaspargase, and selinexor followed by radiotherapy as first-line treatment for patients with newly diagnosed stage I/II extranodal natural killer/T-cell lymphoma (ENKTL).
Timeline
- Start
- 2026-05-06
- Primary completion
- 2028-03-06
- Completion
- 2031-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegaspargase | Protein / enzyme biologic | 2000 unknown | Intramuscular |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |